For both groups:~At inclusion visit :~Patient information and signature of consent form~Randomisation~Previous medical history~Clinical exam~Recording ADCT, EASI, IGA, NRS pruritus, DLQI or CDLQI, EQ-5D-5L~Weekly during 12 months (by patients on https://hestia.chu-nantes.fr) :~Self-assessment of ADCT~Date of dupilumab injections~Batch number of dupilumab~Amount of topical corticosteroids~Visits at M4, M8 and M12 will be performed for :~Clinical exam~Recording secondary end points (EASI, IGA, NRS pruritus, DLQI or CDLQI, EQ-5D-5L) and adverse events~Collect out-of-pocket expenses (M4 and M12).
The goal of this clinical trial is to compare a step-down strategy of spacing dupilumab injections with a standard maintenance treatment in adolescents and adults with controlled Atopic dermatitis (AD) for at least six months. The impact of dosage reduction strategies will be assessed with an innovative primary endpoint: the area under the curve of the weekly ADCT assessment.